Calisa Acquisition Slumps: Why Investors Must Demand Transparency Now
Calisa Acquisition (ALIS) sinks 12% in a biotech market full of opportunists. Low liquidity, weak earnings and opaque leadership explain its 0.33% drop and highlight urgent steps for investor confidence.
3 minutes to read